Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC).

Leucine aminopeptidases (LAPs) were associated with tumor cell proliferation, invasion and/or angiogenesis. LAP3 is one important member of this family. However, its clinical significance and biological function in hepatocellular carcinoma (HCC) remains unknown. In the present study, we demonstrated that LAP3 expression was significantly up-regulated in HCC tissues as well as cells and was closely correlated with lower differentiation, positive lymph node metastasis and high Ki-67 expression, indicating a poor prognosis. Then cell viability assays, flow cytometry assays, wound-healing assays and matrigel invasion assays were performed to demonstrate that LAP3 promoted HCC cells proliferation by regulating G1/S checkpoint in cell cycle and advanced HCC cells migration. Furthermore, we discovered that knockdown LAP3 will enhance the sensitivity of HCC cells to cisplatin, thus promoting the cell death of HCC cells. Collectively, our results indicated that up-regulated expression of LAP3 might contribute to the proliferation and metastasis of HCC. Our data gains greater insight into the cancer-promoting role of LAP3 and its functions in HCC cells, possibly providing potential therapeutic strategies for clinical trials.

[Combined three-dimensional conformal radiotherapy plus transcatheter arterial chemoembolization and surgical intervention for portal vein tumor thrombus in patients with hepatocellular carcinoma].

OBJECTIVE: To explore the clinical therapeutic efficacies of combined three-dimensional conformal radiotherapy (3DCRT) plus transcatheter arterial chemoembolization (TACE) for portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC). METHODS: A total of 145 HCC patients with tumor thrombus in portal vein were divided randomly into 2 groups. Group A (n = 64) was treated with surgical intervention alone while group B (n = 81) underwent 3DCRT plus TACE. The gross tumor volume (GTV) was defined as PVTT only. RESULTS: Survival rates of group A at year 1 and 2 were 40.3% and 21.9% with a mean survival time (MST) of 15.2 months while that of group B were 41.2% and 22.5% with a MST of 15.8 months. The total effective rates of groups A and B was 40.6% (28/64) and 44.4% (36/81) respectively. CONCLUSION: The therapeutic efficacy of 3DCRT plus TACE is similar to that of surgical intervention.